TSX:BCT (Canada)  
BriaCell Therapeutics Corp logo

BriaCell Therapeutics Corp

C$ 7.43 (-1.2%) Dec 2
P/E:
At Loss
P/B:
8.63
Market Cap:
C$ 115.30M ($ 85.44M)
Enterprise V:
C$ 40.77M ($ 30.21M)
Volume:
10.15K
Avg Vol (2M):
6.39K
Also Trade In:
Volume:
10.15K
Market Cap C$:
115.30M
Market Cap $:
85.44M
PE Ratio:
At Loss
Avg Vol (2-Month):
6.39K
Enterprise Value C$:
40.77M
Enterprise Value $:
30.21M
PB Ratio:
8.63
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.24
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 40.4
3-Year EPS without NRI Growth Rate 40.6
3-Year FCF Growth Rate 51.9
Name Current Vs Industry Vs History
5-Day RSI 43.2
9-Day RSI 44.91
14-Day RSI 45.37
6-1 Month Momentum % 14.64
12-1 Month Momentum % -42.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 45
Quick Ratio 45
Cash Ratio 43.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -187.3
Name Current Vs Industry Vs History
ROE % -73.05
ROA % -54.04
ROIC % -2649.89
ROC (Joel Greenblatt) % -3185.07
ROCE % -54.67

Financials (Next Earnings Date:2022-12-14 Est.)

TSX:BCT's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil C$)
EPS (TTM) (C$) -2.213
Beta 1.37
Volatility % 77
14-Day RSI 45.37
14-Day ATR (C$) 0.377364
20-Day SMA (C$) 7.61825
12-1 Month Momentum % -42.95
52-Week Range (C$) 5.32 - 15.05
Shares Outstanding (Mil) 15.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BriaCell Therapeutics Corp Filings

Document Form Filing Date
No Filing Data

BriaCell Therapeutics Corp Analysis

Share your research